medcelerator · clinician one-pager
First FDA-Approved Treatment for Chronic Hepatitis D
Hepcludex (bulevirtide) for chronic hepatitis D (HDV)
Health Canada/FDA Approved · United States, Canada, European Union · September 7, 2026
Condition: Chronic Hepatitis D
Who this is for
Hepcludex (bulevirtide) is the first approved medicine for chronic hepatitis D. The United States gave accelerated approval to a daily 8.5 mg shot in May 2026. Canada and Europe approve a daily 2 mg dose.
Next clinical step
Health Canada and the US Food and Drug Administration (FDA) have approved this medicine. In Canada, the United States and the European Union, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12391cc2-38c2-4cf5-86d3-2be9370127fc
Canada · Prescription
Canada prescription (Health Canada NOC, DIN 02560178)
https://health-products.canada.ca/api/drug/drugproduct/?din=02560178
European Union · Prescription
EU prescription (EC marketing authorisation)
https://www.ema.europa.eu/en/medicines/human/EPAR/hepcludex
European Union · Recruiting clinical trial
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
Combination or different setting. Bulevirtide is the comparator arm; the trial tests brelovitug (phase 3).
https://clinicaltrials.gov/study/NCT07200908
Search all trials on ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=hepatitis%20D&intr=bulevirtide&aggFilters=status:rec
General resources for further research
Canadian Clinical Trial Search Portal (Health Canada)
Health Canada's public search of the drug and biologic clinical trials it has authorised in Canada (phase 1 to 3, since April 2013). Search by condition, drug, or trial status and see where trials are running. It replaced the Health Canada Clinical Trials Database in July 2026. A listing is not enrolment, and Health Canada does not recruit patients: ask your clinician and contact the trial sponsor.
https://clinical-trials-search.canada.ca/en/home
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
CTIS (EU Clinical Trials Information System)
European Union public portal for clinical trials submitted under the Clinical Trials Regulation. Search by medicine, condition, and member state. A CTIS record is not an EMA marketing authorisation and is not enrolment.
https://euclinicaltrials.eu/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/hepcludex-bulevirtide